November 10, 2024 Wall Street Soars: Trump’s Victory Ignites Market Surge
November 2, 2024 Tech Titans’ Mixed Results Stall Wall Street Bull Run
October 28, 2024 Recent Oil Slides In Global Markets, Japan In Flux
Tesla’s Valuation: Unsupported By Fundamentals Or Future Growth
Tesla Stock Doesn’t Deserve This Rally
Nvidia: Q3 Earnings Could Ignite $200 Rally
Tesla: When Fundamentals Don’t Matter (Rating Downgrade)
Amazon Q3: Stop Buying The Stock For Now Because It’s Overvalued
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Pfizer (PFE) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: November 14, 2024 (10:35)
Sector: HealthcareThe share price of Pfizer Inc. (PFE) now
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 4 (1/3/0) |
Previous Week
|
Bullish | Opinions: 2 (2/0/0) |
Two Weeks Ago
|
Bullish | Opinions: 4 (2/2/0) |
Three Weeks Ago
|
Bullish | Opinions: 1 (1/0/0) |
Are you interested in Pfizer Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Pfizer stock price in 2024, 2025, 2026. How much will one Pfizer share be worth in 2024 - 2026?
When should I take profit in Pfizer stock? When should I record a loss on Pfizer stock? What are analysts' forecasts for Pfizer stock? What is the future of Pfizer stock? We forecast Pfizer stock performance using neural networks based on historical data on Pfizer stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Pfizer stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Pfizer shares. This happens once a day.
Historical and forecast chart of Pfizer stock
The chart below shows the historical price of Pfizer stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Pfizer stock price can be found in the table below.
Long-term forecasts by years.
Pfizer Inc. Analysts predictions review
As of now, Panda has combed through 11 analytical articles which are directly related to PFE from the last 30 days. Out of these, 6 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 5 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Oct 20, 2024 to Nov 11, 2024.
Pfizer's Dividend Dilemmas: Navigating Growth and Shareholder Value
In this review of the analytical financial article by Sensor Unlimited, we delve into the author's informed decision to maintain a no stance on PFE stock. Sensor Unlimited, an active contributor since 2021, has published 1,090 articles, showcasing remarkable productivity and dedication to delivering insightful financial perspectives. With 8,833 subscribers, their viewpoints resonate widely within the investment community. The author's analytical insights are underscored by their excellent credibility, highlighting their expertise and authority, which ascend them beyond most peers in the field. Given these credentials, Sensor Unlimited's assessment of PFE stock is not only informed by data but also shaped by a reputation for reliable and well-regarded commentary in the financial sector. This background provides a robust context for understanding their current stance on PFE.
Key Theses of the Article
- A review of AbbVie and Pfizer's recent earnings reports with a focus on dividends.
- The analysis is aligned with Peter Lynch's insights into dividend stocks.
- The article outlines an upgrade in the ABBV stock and a downgrade in PFE stock.
- Attention is drawn to the PEGY ratio and alterations in their buyback programs.
Key Factors Influencing PFE's Stock Price
Dividend Strategy and Yield
Pfizer's dividend policy is critical as it directly impacts investor return expectations and confidence. A strong or growing yield can drive stock price appreciation or stabilization in the near term.
PEGY Ratio
The PEGY ratio, reflecting growth and yield, signals undervaluation or overvaluation. A lower PEGY suggests better valuation and could attract more investors, impacting stock price positively.
Buyback Program Changes
Changes in Pfizer's buyback programs suggest the company's approach to shareholder value and capital utilization. Increasing buybacks may lead to a rise in stock price due to the reduced share count and a signal of strong cash flow.
Review the original AnalysisPfizer's 6%+ Dividend: A Mirage Amidst Patent Challenges and Modest Growth
In the following review of KM Capital's analytical financial article, we delve into the author’s insights while they maintain a Neutral stance on PFE stock. Since joining the platform in 2024, KM Capital has produced an impressive 110 publications, signaling an active and engaged presence in financial discussions. With a subscriber base of 3,040 readers, it's clear KM Capital has garnered a level of popularity that underscores the relevance of their analyses within the community. However, while the author is industrious, contributing frequently in a relatively short period, the credibility of their viewpoints is deemed low based on the current metrics. As we explore their perspective on PFE stock, we aim to provide a well-rounded understanding of its potential market trajectory, drawing from KM Capital's neutral position.
Key Theses from the Review
- Pfizer's stock has underperformed compared to the S&P 500 and faces challenges from patent expirations and competition.
- Despite a positive Q3 earnings surprise, Pfizer's profitability remains weaker than pre-pandemic levels.
- Valuation analysis suggests that Pfizer's stock is fairly valued with no significant upside potential.
- The company's market share in oncology is modest, and its financials are weaker compared to leading competitors.
- High R&D spending and strong operating cash flow support potential new product development and sustainable dividends.
Factors Influencing Pfizer's Stock Price
Patent Expirations
Patent expirations for key products pose a significant threat to one third of Pfizer's sales, leading to potential significant price erosion and market share loss. This large portion of sales at risk due to patent cliffs is a critical factor impacting stock performance.
Q3 Earnings Performance
The Q3 earnings beat consensus, but did not impress investors due to ongoing profitability challenges, indicating mixed investor sentiment towards financial health improvements. The guidance upgrade failed to significantly impact stock pricing, reflecting investor caution.
Oncology Market Position
Pfizer's modest oncology market share and weaker relative financial strength compared to competitors like Bristol Myers Squibb and Merck indicate challenges in expanding within this competitive drug segment. Given the strategic focus on oncology, this has substantial implications for future growth plans.
Dividend Yield
The 6.3% forward dividend yield remains attractive to income-seeking investors, suggesting stability in stock price due to sustained interest amidst broader financial risks. High R&D spending and sustainable cash flow back this dividend outlook, providing fiscal support.
R&D Spending
Aggressive R&D efforts facilitate future product launches, aligning with leading industry benchmarks like BMY. The potential for new compelling product developments presents medium-term growth prospects that might enhance stock valuation if results materialize.
Review the original AnalysisCommentary
Pfizer's current standing in the stock market presents a neutral horizon. Key influences include patent expirations threatening a third of sales, which significantly pressures the stock with a high significance score of 8. Despite delivering a Q3 earnings beat, ongoing profitability hurdles linger, leaving investor confidence lukewarm with a significance of 6. The average influence strength of these elements suggests a stability-focused market reaction over the next 15 days, with caution given to the broader financial implications tied to patent cliffs.
In a 30-day span, the significance of Pfizer’s high R&D spending (scoring 5) and strong forward dividend yield (scoring 6) could offer some cushioning against the competitive market pressures, driven by a moderate market interest in the company’s long-term R&D outcomes. The modest oncology foothold (scoring 7) also underlines the neutral trend; there's potential in oncology, but Pfizer faces tough competition. Overall, these factors average out to maintain a steady state in stock positioning, reflecting ongoing investor hesitancy but also the potential for a more positive swing if new developments succeed.
The Bright Future of PFE Stocks: An Unfolding Opportunity
In the world of high-stakes investing, few opportunities are as compelling as the case of Pfizer Inc. (NYSE:PFE). This pharmaceutical giant, standing on the threshold of its 176th year, has experienced a roller coaster in the stock market, touching a decade-low low of $26.93 per share. To understand the PFE stock forecast, it is crucial to investigate the events and factors poised to influence its performance.
The capability to predict PFE stock rates with high accuracy hinges significantly on analyzing the company’s strong fundamentals and upcoming market dynamics. Recently, the valuation of Pfizer has reached a depressed level, essentially providing a lucrative buying opportunity. Despite facing a decline in COVID-19 related product sales, Pfizer reported a commendable 7% operating sales growth in 2023, propelled by new product launches and the consistent growth of existing ones.
Factors Influencing PFE Stock Performance
Looking ahead, several core elements will play pivotal roles in shaping Pfizer’s stock trajectory. Firstly, the heavy influx of COVID-19 related revenue has bolstered Pfizer’s financial position, rendering the acquisition of Seagen—a leader in antibody-drug conjugate technology—a strategic masterstroke. This move positions Pfizer ahead in a competitive race within the pharma industry.
Moreover, while some of Pfizer’s key drugs are on the verge of hitting a patent cliff, the company’s robust and diverse pipeline promises not just to offset, but potentially eclipse, any potential shortfalls. Given these dynamics, forecasting a substantial upside for PFE stock seems not just optimistic but grounded in tangible facts and figures.
In conclusion, when contemplating the PFE stock buy or sell dilemma, it’s imperative to consider the projected EPS growth, the anticipated rise in EBITDA margins, and the transformative potential of Pfizer’s product pipeline. With an attractive dividend yield forecast of 6.19% for FY2024, the question isn’t so much ‘will PFE stock go up?’ but rather, ‘how high?’ As such, the PFE stock price target points towards an optimistic upward trend, making PFE stock an attractive proposition for both investors and analysts alike.
Pfizer Inc. stands tall as one of the global giants in the pharmaceutical industry, hailing from the United States. This powerhouse is behind a suite of well-known medications that have become household names. They’ve got Lipitor to keep cholesterol in check, Lyrica for nerve and muscle pain relief, Diflucan as an antifungal go-to, and Zithromax for bacterial infections.
There’s also the famed blue pill, Viagra, giving hope to those grappling with erectile dysfunction, while Celebrex battles arthritis and other forms of pain. Sermion comes to the aid of those with cognitive issues, Dostinex addresses hormonal imbalances, and Champix lends a hand to those determined to quit smoking.
Pfizer daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Nov 16 | 26.87 | 26.27 | 27.23 | 3.62 |
Nov 17 | 27.19 | 26.57 | 27.42 | 3.19 |
Nov 18 | 26.51 | 25.97 | 26.84 | 3.37 |
Nov 19 | 25.84 | 25.47 | 26.03 | 2.19 |
Nov 20 | 26.13 | 25.65 | 26.68 | 4.04 |
Nov 21 | 26.39 | 25.93 | 26.87 | 3.60 |
Nov 22 | 26.65 | 26.11 | 26.82 | 2.72 |
Nov 23 | 26.49 | 26.19 | 27.08 | 3.40 |
Nov 24 | 25.76 | 25.43 | 26.22 | 3.10 |
Nov 25 | 25.66 | 25.41 | 25.85 | 1.73 |
Nov 26 | 25.07 | 24.64 | 25.27 | 2.53 |
Nov 27 | 25.66 | 25.12 | 26.05 | 3.71 |
Nov 28 | 26.26 | 25.72 | 26.45 | 2.85 |
Nov 29 | 26.05 | 25.47 | 26.59 | 4.42 |
Nov 30 | 26.19 | 25.70 | 26.54 | 3.27 |
Dec 01 | 25.81 | 25.64 | 26.13 | 1.90 |
Dec 02 | 26.19 | 25.66 | 26.66 | 3.89 |
Dec 03 | 25.98 | 25.79 | 26.29 | 1.93 |
Dec 04 | 25.77 | 25.27 | 25.93 | 2.60 |
Dec 05 | 25.45 | 25.15 | 26.02 | 3.46 |
Dec 06 | 25.14 | 24.88 | 25.47 | 2.36 |
Dec 07 | 25.23 | 24.66 | 25.45 | 3.22 |
Dec 08 | 25.98 | 25.56 | 26.26 | 2.71 |
Dec 09 | 26.11 | 25.51 | 26.67 | 4.54 |
Dec 10 | 26.01 | 25.49 | 26.62 | 4.44 |
Dec 11 | 26.65 | 26.17 | 27.25 | 4.12 |
Dec 12 | 26.12 | 25.66 | 26.72 | 4.15 |
Dec 13 | 25.59 | 25.35 | 26.01 | 2.60 |
Dec 14 | 24.93 | 24.36 | 25.14 | 3.19 |
Dec 15 | 25.01 | 24.85 | 25.58 | 2.93 |
Pfizer Daily Price Targets
Pfizer Stock Forecast 11-16-2024.
Forecast target price for 11-16-2024: $26.87.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.494%.
Pessimistic target level: 26.27
Optimistic target level: 27.23
Pfizer Stock Forecast 11-17-2024.
Forecast target price for 11-17-2024: $27.19.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.094%.
Pessimistic target level: 26.57
Optimistic target level: 27.42
Pfizer Stock Forecast 11-18-2024.
Forecast target price for 11-18-2024: $26.51.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.259%.
Pessimistic target level: 25.97
Optimistic target level: 26.84
Pfizer Stock Forecast 11-19-2024.
Forecast target price for 11-19-2024: $25.84.
Negative dynamics for Pfizer shares will prevail with possible volatility of 2.145%.
Pessimistic target level: 25.47
Optimistic target level: 26.03
Pfizer Stock Forecast 11-20-2024.
Forecast target price for 11-20-2024: $26.13.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.879%.
Pessimistic target level: 25.65
Optimistic target level: 26.68
Pfizer Stock Forecast 11-21-2024.
Forecast target price for 11-21-2024: $26.39.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.477%.
Pessimistic target level: 25.93
Optimistic target level: 26.87
PFE (PFE) Monthly Stock Prediction for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Dec. | 26.91 | 25.24 | 28.54 | 11.54 |
Pfizer forecast for this year
Pfizer Stock Prediction for Dec 2024
An uptrend is forecast for this month with an optimal target price of $26.9124. Pessimistic: $25.24. Optimistic: $28.54
Pfizer (PFE) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 27.52 | 26.40 | 29.13 | 9.35 |
Feb | 28.58 | 27.04 | 29.79 | 9.24 |
Mar | 28.25 | 26.98 | 29.72 | 9.24 |
Apr | 26.16 | 25.03 | 26.80 | 6.59 |
May | 26.38 | 24.88 | 26.85 | 7.34 |
Jun | 28.70 | 26.71 | 29.55 | 9.61 |
Jul | 27.49 | 25.78 | 29.00 | 11.09 |
Aug | 27.74 | 27.21 | 29.53 | 7.86 |
Sep | 27.71 | 26.29 | 29.13 | 9.76 |
Oct | 25.59 | 23.77 | 26.17 | 9.15 |
Nov | 26.30 | 24.98 | 27.09 | 7.78 |
Dec | 26.45 | 25.28 | 26.99 | 6.35 |
Pfizer (PFE) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 28.11 | 26.39 | 29.76 | 11.31 |
Feb | 28.75 | 27.76 | 29.99 | 7.42 |
Mar | 29.42 | 27.62 | 30.82 | 10.39 |
Apr | 29.34 | 27.83 | 30.87 | 9.84 |
May | 30.66 | 28.56 | 32.26 | 11.46 |
Jun | 30.77 | 28.69 | 32.49 | 11.68 |
Jul | 29.36 | 27.43 | 31.36 | 12.55 |
Aug | 30.18 | 29.44 | 31.59 | 6.79 |
Sep | 29.44 | 28.38 | 30.29 | 6.30 |
Oct | 27.48 | 26.47 | 28.87 | 8.31 |
Nov | 26.57 | 25.06 | 27.09 | 7.50 |
Dec | 26.06 | 25.20 | 26.91 | 6.36 |
Pfizer information and performance
235 E 42ND ST, NEW YORK, NY, US
Market capitalization of the Pfizer Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PFE shares in the company outstanding by the market price of one share.
EBITDA of Pfizer is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Pfizer (PFE) stock dividend
Pfizer last paid dividends on 11/08/2024. The next scheduled payment will be on 12/02/2024. The amount of dividends is $1.67 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.
Commentary
Looking slightly further, the changes in Pfizer's buyback programs hint at broader strategic moves. These carry an increased significance, reflecting the company's commitment to maintaining shareholder value through efficient capital allocation. The stock may experience moderate appreciation over the next month as these changes surface, further reinforced if accompanied by strong cash flows. Thus, while there may not be a dramatic surge, steady investor confidence linked to dividends and buybacks will likely uphold Pfizer's stock stature. These factors lead to a consideration of a 'Neutral' trend given the balancing forces at play.